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Abstract
Electroconvulsive therapy (ECT) is considered an effective treatment for major depression
with melancholic features. However, neurocognitive side-effects such as anterograde
amnesia still regularly occur. The present study aims to evaluate the severity and course
of anterograde amnesia in severely depressed patients undergoing ECT. In a prospective
naturalistic study, anterograde memory function was assessed among inpatients who
underwent ECT (n = 11). Subjects met DSM-IV criteria for major depressive disorder.
Recruitment took place between March 2010-March 2011 and March 2012-March 2013.
Controls treated with antidepressants (n = 9) were matched for age, gender and depression
severity. Primary outcome measure was immediate recall; secondary outcome measures
were delayed recall, recognition, and visual association. Differences were tested using
repeated measures ANOVA and paired t-tests. Correlations with hypothesized covariates
were calculated. In patients with major depressive disorder, ECT had a significant effect on
delayed memory function (p<0.01 with large effect sizes). Findings on immediate recall
were less consistent. Four weeks after treatment discontinuation, these memory functions
had recovered. Age was identified as a very important covariate. The main limitations of our
study are its naturalistic design, possibly compromising internal validity, and its small sam-
ple size. However, if these findings can be reproduced in a more comprehensive study
group, then the possible induction of anterograde amnesia is not a justifiable reason for cli-
nicians to disregard ECT as a treatment option.
Introduction
Electroconvulsive therapy (ECT) is considered an effective treatment for major depression
with melancholic features (MDm), especially in psychotic depression [1]. ECT is also effective
when previous pharmacotherapy has failed [2] and is relatively well tolerated [1]. However,
despite multiple technical adjustments over the decades, neurocognitive side-effects still
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regularly occur. These may consist of decreased functioning in both anterograde and retro-
gradememory, as well as postictal disorientation and impairments in processing speed, verbal
fluency, attention and executive functioning [3]. Although the underlyingmechanisms remain
to be elucidated, it is suggested that these side-effectsmay be temporary [4].
In a meta-analysis, reasonable evidencewas found that cognitive side-effects associated with
ECT are limited to the first three days after finishing ECT and that afterward,most improve
beyond baseline [3]. However, primary studies on the particular subject of anterograde amne-
sia in relation to ECT are inconclusive concerning its severity and course [5–7].
An association has been reported betweenMDm and neurocognitive impairment, also in
patients who did not receive ECT. In particular, explicit memory seems to be affected which
may cause anterograde and retrograde amnesia, whereas implicit memory seems to be spared
[8].
In this context, however, anterograde amnesia has not yet been extensively studied.
Our study therefore focuses on anterograde amnesia in severely depressed inpatients who
are treated with ECT, focusing on both its severity and course. To meet our goals, we formu-
lated the following research aims: 1) to compare the severity of anterograde amnesia during
and after ECT with pharmacotherapy in severely depressed inpatients, and 2) to compare the
course of anterograde amnesia during and after ECT with pharmacotherapy in severely
depressed inpatients. We hypothesize that 1) anterograde amnesia will be of greater severity in
ECT, compared with pharmacotherapy and that 2) compared to baseline, the severity of anter-
ograde amnesia in ECT will increase compared with pharmacotherapy.
Methodology
Patient selection
Design. The course and extent of anterograde amnesia following ECT were studied using
a naturalistic prospective design in patients with MDm. Patients treated with ECT were com-
pared with a control group of depressed inpatients treated with antidepressants. This study was
carried out in accordance with the latest version of the Declaration of Helsinki and approved
by the Medical Ethics Committee of Erasmus Medical Center. All patients provided written
informed consent after the study procedures had been fully explained.
Participants and setting. Recruitment took place betweenMarch 2010-March 2011 and
March 2012-March 2013. Inpatients at Erasmus Medical Center diagnosedwith MDm either
with or without psychotic features, and for whom ECT was indicated, were considered eligible
to participate: patients aged 18–90 years who consented to participate were included. During
the second year (2012–2013) inpatients at Delta Psychiatric Hospital (Rotterdam, The Nether-
lands) meeting the same criteria were also considered eligible and were included after provid-
ing informed consent. The control group consisted of inpatients with MDm (with or without
psychotic features) who were matched for age, gender and depression severity. Diagnosis was
confirmedwith the Schedule of AffectiveDisorder and Schizophrenia [9] and depression sever-
ity was assessed with the Hamilton Rating Scale for Depression [10].
Exclusion criteria. Patients admitted for acute ECT treatment were excluded as they
could not be given sufficient time to consider their participation. Patients with pre-existing
cognitive impairment, defined as a baseline score 24 on the Mini Mental State Evaluation
(MMSE, range 0–30), were also excluded [11]. Other exclusion criteria were co-morbid alcohol
or drug abuse, and a lifetime diagnosis of dementia or other cognitive disorder. The use of lith-
ium was also considered as a possible exclusion criterion, because an adverse effect on cognitive
functioning has been suggested [12]: however, as this is topic is still under debate, we decided
to include these patients. Fig 1 summarizes the patient selection procedure.
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Interventions and clinical evaluation
Patients in the ECT group were withdrawn from all psychotropic medication at least 1 week
before the first ECT treatment and maintained drug-free during the course of ECT. ECT was
performedwith the Thymatron System IV (Somatics Inc, Lake Bluff, Ill, USA); pulse width was
set at 0.5 msec and energy used varied from 150 mC to 750 mC (mean dose of first ECT treat-
ment was 75 mC; mean value throughout the course of ECT was 305 mC). The mean number
of ECT treatments was 12.6 (median 14). Anesthesia was achieved with intravenously adminis-
tered etomidate (0.2 mg/kg) and succinylcholine (1.0 mg/kg) for muscle relaxation. Bilateral
ECT was administered twice a week. During ECT, physiological monitoring included pulse
oximetry and blood pressure measurement, and an electrocardiogram.Seizure duration was
determined using a 2-lead electroencephalographand the cuff technique [13]. During the first
ECT treatment, the seizure threshold was determinedwith stimulus titration. If the starting
stimulus dose failed to elicit a seizure of at least 25-s duration measured with the cuff tech-
nique, the stimulus dose was increased according to the titration schedule (Table 1) and the
patient was restimulated after 30 s. For the second treatment, the stimulus dosage was set at 1.5
times the defined seizure threshold. During the ECT course, stimulus dosage settings were
adjusted upward to maintain a seizure duration of at least 25 s as measured with the cuff
method. ECT was continued until patients were either asymptomatic (HRSD<8) or showed
no further improvement (i.e. decrement on the HRSD) during 3 consecutive treatments.
Patients in the ECT group were tested at least 24 h after an ECT session. If patients in the
control group used psychotropic medication at the time of inclusion, this medication was
stopped at least 1 week before receiving a new course of treatment with antidepressants. Dosing
was based on the following predefined blood levels: 200–300 ng/ml for imipramine, 50–150
ng/ml for nortryptyline and 0.60–0.80mmol/L for lithiumcarbonate. Tranylcypromine was
dosed at 70 mg/day. In all patients, depression severity was routinely assessed everyweek dur-
ing treatment with the 17-item HRSD [10]: for the present study we collected data following
the scheme presented by Fig 1.
Outcome measures
Selectionof tests. There is little evidence as to which tests adequately measure anterograde
amnesia in depressed patients undergoing ECT. One study reported that verbal learning tasks
Fig 1. Flowchart of patient selection in the electroconvulsive therapy (ECT) group. %M = proportion of missing values over T0-T3;
#incomplete data were replaced by mean values; *assessments are defined as follows: T0 = baseline. In the ECT group, T1 = 2 weeks
after start of ECT; T2 = 4 weeks after start of ECT; T3 = 4 weeks after discontinuation of ECT. In the control group, assessments are
defined as follows: T1 = 2 weeks after reaching adequate blood level of antidepressants; T2 = 4 weeks thereafter; T3 = 8 weeks
thereafter. RAVLT = Rey Auditory Verbal Learning Test; VAT = Visual Association Test; HRSD = Hamilton Rating Scale for Depression;
MMSE = Mini Mental State Examination.
doi:10.1371/journal.pone.0165392.g001
Table 1. ECT dose titration schedule.
Dose level Energy level (%) Charge (mCoulomb)
1 5 25
2 10 50
3 20 101
4 40 202
5 60 302
6 80 403
At age < 50 the schedule is started at dose level 1, at age 50, the schedule begins with dose level 2.
doi:10.1371/journal.pone.0165392.t001
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are relatively sensitive to the effects of ECT [14]; these authors also found that immediate and
delayed recall-subtests of the Rey Auditory Verbal Learning Test (RAVLT; see below) could
adequately detect cognitive changes in patients who underwent ECT [15,16]. For the present
study, this was an important consideration to choose the RAVLT as our main test. Because psy-
chometric characteristics are slightly in favor of the immediate recall subtest [17], scores on this
subtest are our primary outcomemeasure. Nonverbal memory tests are reported to have incon-
sistent sensitivity to ECT [14]. The Visual Association Test (VAT) adequately detects dementia
at an early stage but (as far as we know) has not been tested in our specific subgroup of patients
[18]. The VAT was used to validate findings on our primary outcomemeasure.With reassess-
ments, because scores on memory tests may be influencedby a learning effect, alternating ver-
sions of the RAVLT and the VAT were used to reduce this effect to a minimum [17].
Primary outcome measure. Immediate recall, subtest of the RAVLT: translated Dutch
version [16].
This test has high internal consistency (Cronbach's α> 0.80) and high test-retest reliability
(r ranges from 0.61–0.86) [17]. The assessor sums up a list of 15 unrelated monosyllabic words
repeated over five different trials: participants are asked to repeat these after each trial (scores
range from 0–15, with higher scores indicating better anterograde memory function).
Secondaryoutcome measures.
1. Delayed recall, subtest of the RAVLT: 20 min after the fifth trial (see Primary outcome
measure). Delayed recall is tested by asking the participant to repeat the previously men-
tioned 15 words again (range 0–15).
2. Recognition, subtest of the RAVLT. Recognition is tested by summing 30 words, 15 of
which were in the previous trials: score on recognition is defined as the total number of cor-
rectly identifiedwords added to the total number of correct rejections (range 0–30). Test-
retest reliability correlation coefficients for delayed recall and recognition subtests range
from 0.51–0.72 [17].
3. Immediate recall by the VAT [18]: for this test the internal consistency (Cronbach's α>
0.80) and test-retest reliability (r = 0.72) are high. The test consists of six cue cards which
depict one object, these cards are shown first. Then six association cards are shown, which
depict a combination of the cue plus a target object. After this, the six cue cards are shown
again; the participant is then asked for the (now missing) target object. Score ranges from
0–6, with a maximum score indicating intact anterograde memory function.
Covariates
Because age [19], the presence of psychotic features [20] (confirmedby the SADS [9]), and sever-
ity of depressive symptoms [21] (measured by the HRSD [10]) may affect cognitive functioning,
these were defined as covariates. With regard to depression severity, both baseline severity and
percent change of mood compared to baseline during the study were tested as covariates.
Statistical analysis
Differences between the ECT and control group at baseline were tested with t-tests for continu-
ous variables (age, depression severity) and Chi2 or Fisher exact tests (FET) for categorical vari-
ables (psychotic features, gender). At each assessment, differences in cognitive functioning
between assessments, and differences between the ECT and control group, were tested using
(paired) t-tests. Subsequently, repeated measures ANOVAs were used to test whether the
course of cognitive functioning differs over time between the two groups. Data were checked
Anterograde Amnesia, Depression and ECT
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visually for non-normality using Q-Q plots. Missing data were replaced by the mean value.
Correlations between the covariates and outcome measures were assessed by calculating Pear-
son’s r. Furthermore, the variable was entered as a covariate into the ANOVA analysis. Addi-
tionally, Cohen’s f for ANOVA and Cohen’s d for differences in means [22] were used to
determine effect sizes: an f of 0.1 and a d of 0.2–0.3 is considered a small effect, an f of 0.25 and
a d around 0.5 a medium effect, an f of 0.4 and a d of 0.8 and higher as a large effect.
Power calculation
Very few studies quantified the impact of ECT on anterograde amnesia. In line with a more
recent study by Bodnar et al. [23], we decided that a 5 point difference between ECT and con-
trol patients on mean scores on the RAVLT over the full course of the study could be inter-
preted as a clinically significant increase of anterograde amnesia. This equals to a medium
sized treatmentmeasurement interaction-effect (f = 0.33). To detect a medium-sized effect at
5%-significance level and with a power of 80% (assuming a correlation among the 4 measure-
ments of r = 0.25), we needed a sample size of 20 patients. All calculations were performed
with IBM SPSS Statistics 20.
Follow-up after recruitment
Initially, 13 patients were recruited in the ECT group and 11 in the control group.
In the ECT group, 1 patient dropped-out and 1 was visually identified as an outlier, leav-
ing11 patients available for analysis. In the control group, 1 patient dropped-out and 1 was
visually identified as an outlier, leaving 9 patients available for analysis. One additional patient
from the control group was excluded from the analysis for the VAT due to dropout after base-
line measurement: therefore, 8 control patients entered the analysis.
The number of subjects with previous pharmacotherapy failure was 10 in our ECT group
and 6 in our control group. One patient in our ECT group was diagnosedwith a comorbid
obsessive compulsive disorder, for which clomipramine was continued during the study: all
other included patients were diagnosedwith MDm only.
Two patients in the ECT group were recruited at the Delta Psychiatric Hospital and all oth-
ers (in both groups) were recruited at the psychiatry ward of Erasmus Medical Center.
Regarding covariates, the number of included patients with psychotic features was too small
to determine correlation or to perform further analyses. Although we consideredmaking an
additional assessment at 6 months after discontinuation of ECT, because dropout rates at that
time were very high we did not include this assessment in the present analysis. Fig 1 presents
an overviewof the flow of participants through the study.
Results
Group characteristics
The analyses included 11 patients undergoing ECT and 9 patients treated with antidepressants.
Matching for age, gender and depression severity was successful (Table 2).
Anterograde amnesia
Covariates. Age. In the ECT group, age at baseline was strongly correlated with immediate
recall (r = 0.84; p<0.01) and in the control group these variables were moderately correlated
(r = 0.35; p = 0.36).
Depression severity. In the ECT group, baselineHRSD scores were positively correlated
with immediate recall (r = 0.60; p = 0.05), whereas in the control group baseline HRSD scores
Anterograde Amnesia, Depression and ECT
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were negatively correlated with immediate recall (r = -0.44; p = 0.23). This was not consistent
with our expectations and is discussed below.
Change in depression severity. In both groups, percent change in depression severity was
negatively correlated with scores on immediate recall. In the ECT group we found a moderate
correlation (r = -0.28; p = 0.41) and in the control group a weak correlation (r = -0.12;
p = 0.76).
Primary outcome measure: immediate recall. We found a significant effect over time (F
(3,54) = 3.960; p = 0.013), but not between both groups (F = 2.568; p = 0.126). The data showed
no significant timetreatment interaction effect on immediate recall (F(3) = 0.976; p = 0.411;
f = 0.23) (Fig 2).
Adjusting for age did not result in a significant timetreatment interaction effect (F(3) =
1.34; p = 0.27; f = 0.28), nor did adjustment for depression severity at baseline (F(3) = 1.00;
p = 0.40; f = 0.24) or adjustment for mood change (F(3) = 0.83; p = 0.49; f = 0.22). However,
adjusting for age considerably lowered the p-value and slightly increased f, suggesting that age
may be a relevant factor in this study.
In the ECT group, immediate recall decreased at trend level statistical significance between
T0 and T2 (T(10) = 2.00; p = 0.07; d = 0.38) and increased significantly betweenT2 and T3 (T
(10) = -2.54; p = 0.03; d = 0.92). In the control group, immediate recall increased significantly
betweenT0 and T3 (T(8) = -2.86; p = 0.02; d = 0.89). Compared to the control group, the ECT
group scored lower at T3. Results are summarized in Table 3.
Table 2. Characteristics of the two study groups.
ECT (n = 11) Control (n = 9)
Demographics
Male:female 5:6 3:6 FET: p = 0.67
Mean age in years (SD) 59.55 (15.3) 56.11 (12.1) T(18) = 0.55; p = 0.59
Primary diagnosis at baseline
MDm without psychotic symptoms 8 8 FET: p = 0.59
MDm with psychotic symptoms 3 1
Depression severity and global cognitive functioning
HRSD (SD) baseline 23.64 (5.3) 25.00 (3.1) T(18) = 0.68; p = 0.50
HRSD (SD) at T3a 12.30 (5.8) 16.88 (6.4) T(18) = 1.67; p = 0.11
%change HRSD (SD) 0.46 (0.3) 0.30 (0.3) T(18) = 1.07; p = 0.30
MMSE (SD) baseline 27.38 (2.5) 28.00 (2.9) T(13) = 0.45; p = 0.66
Treatment
ECT–right unilateral 1b -
ECT–bilateral 10 -
imipramine - 4
nortriptyline - 2
imipramine and lithium - 2
tranylcypromine - 1
clomipramine 1b 0
mirtazapine and lithium 1b 0
ECT = electroconvulsive therapy; MDm = major depression with melancholic features; HRSD = Hamilton Rating Scale for Depression; MMSE = Mini Mental
State Examination; FET = Fisher’s exact test.
a T3 in the ECT group is defined as 4 weeks after discontinuation of ECT and in the control group as 8 weeks after reaching adequate blood level of
antidepressants.
bviolation of protocol.
doi:10.1371/journal.pone.0165392.t002
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Secondaryoutcome measures. Results for all secondary outcome measures are summa-
rized in Table 3.
Delayed recall. We didn't find a significant effect over time (F(3,54) = 1.978; p = 0.128), nor
between both groups (F = 3.552; p = 0.076). However, the timetreatment interaction effect on
delayed recall was significant (F(3) = 5.43; p<0.01; f = 0.55), which can interpreted as a differ-
ent course of delayed recall function in patients in the ECT group, compared to its course in
control patients. Adjustment for age resulted in a very slightly lowered p-value and a slightly
increased f (F(3) = 6.28; p<0.01; f = 0.61), and so did adjustment for mood change (F(3) =
6.08; p<0.01; f = 0.60). Adjustment for baseline depression severity resulted in a similar p-
value and a very slightly increased f (F(3) = 5.48; p<0.01; f = 0.57).
Fig 2. Results for repeated measures ANOVA on immediate recall (with +/- 1 SE). Repeated measures ANOVA showed
no significant differences. However, the within-group effect (using paired t-tests) was significant between T2 and T3 in the
ECT group (1; p = 0.03) and between T0 and T3 in the control group (2; p = 0.02). T0 = baseline. In the ECT group, T1 = 2
weeks after start of ECT; T2 = 4 weeks after start of ECT; T3 = 4 weeks after discontinuation of ECT. In the control group,
assessments are defined as follows: T1 = 2 weeks after reaching adequate blood level of antidepressants; T2 = 4 weeks
thereafter; T3 = 8 weeks thereafter.
doi:10.1371/journal.pone.0165392.g002
Anterograde Amnesia, Depression and ECT
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In the ECT group, scores at T2 were lower compared to baseline (T(10) = 4.30; p<0.01;
d = 1.06) and scores at T3 were higher compared to those at T2 (T(10) = -4.45; p<0.01;
d = 1.30). Compared to the control group, the ECT group had lower scores at T2.
On the recognition and visual association tasks, no significant effect was found between
assessments in the ECT group (d ranged from 0.03–0.64 and from 0.07–0.39, respectively) or
between the ECT and control group (d ranged from 0.04–0.40 and from 0.13–0.37, respec-
tively), and there was no timetreatment interaction effect (f = 0.01 and 0.06, respectively).
Discussion
Anterograde amnesia
The primary finding of our study is that the course of delayed recall function in severely
depressed inpatients undergoing ECT is significantly impaired, compared to patients who are
treated with antidepressants. Delayed recall function in the ECT group recovered within four
weeks after treatment discontinuation. These results are consistent with an uncontrolled study
[15], in which significant effects of ECT were found on immediate (n = 28) and delayed
(n = 26) recall between the 3rd and 4th treatment session.
In immediate recall, we found a decrease of function during ECT, however, statistically this
finding did not reach significance.Also, we found that immediate recall function improved
within four weeks of treatment discontinuation. Our findings support the hypothesis that
anterograde amnesia may be a temporary effect of ECT.
Table 3. Mean values (SD) of all outcome measures, between-group comparisons, and effect sizes at
each time of assessment.
ECT Control d
Immediate recall (n = 11; n = 9)
T0 31.55 (11.0) 33.78 (8.5) T(18) = -0.50; p = 0.62 -0.23
T1 30.00 (9.3) 37.56 (11.0) T(18) = -1.67; p = 0.11 -0.74
T2 27.91 (7.7) 35.00 (13.7) T(18) = -1.46; p = 0.16 -0.64
T3 34.00 (5.4) 40.29 (6.0) T(18) = -2.48; p = 0.02 -1.11
Delayed recall (n = 11; n = 9)
T0 6.5 (3.2) 6.3 (2.8) T(18) = 0.16; p = 0.88 0.07
T1 5.3 (2.6) 7.9 (3.4) T(18) = -1.98; p = 0.06 -0.86
T2 3.5 (2.4) 7.8 (3.8) T(18) = -3.16; p = 0.01 -1.35
T3 6.5 (2.2) 7.7 (2.5) T(18) = -1.15; p = 0.27 -0.51
Recognition (n = 11; n = 9)
T0 27.3 (3.5) 26.3 (3.7) T(18) = 0.58; p = 0.57 0.28
T1 24.7 (4.4) 26.4 (4.2) T(18) = -0.89; p = 0.39 -0.40
T2 26.5 (3.1) 26.4 (4.7) T(18) = 0.09; p = 0.93 0.03
T3 26.6 (3.7) 26.3 (3.3) T(18) = 0.19; p = 0.85 0.09
VAT (n = 11; n = 8)
T0 5.1 (1.1) 5.5 (1.1) T(17) = -0.79; p = 0.44 -0.36
T2 5.2 (1.4) 5.0 (1.4) T(17) = 0.28; p = 0.78 0.14
T3 5.5 (0.6) 5.6 (0.7) T(17) = -0.35; p = 0.73 -0.15
Bold indicates significant value. T0 = baseline. In the ECT group, T1 = 2 weeks after start of ECT; T2 = 4
weeks after start of ECT; T3 = 4 weeks after discontinuation of ECT. In the control group, assessments are
defined as follows: T1 = 2 weeks after reaching adequate blood level of antidepressants; T2 = 4 weeks
thereafter; T3 = 8 weeks thereafter. Results are uncorrected for multiple comparisons.
doi:10.1371/journal.pone.0165392.t003
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From baseline onward, immediate recall functionwas impaired in the ECT group compared
to the control group, reaching significance (with a large effect size) four weeks after discontinu-
ation of ECT. Although further recovery of immediate recall function could be expected, the
study was terminated at this point due to a high dropout before the (planned) last assessment.
In the control group, immediate recall improved significantly compared to baseline, which
might be attributed to successful treatment of depression as well as to their treatment: these
patients did not receive ECT so they were not exposed to the, in our article discussed, risk of
cognitive deterioration caused by ECT.
In Fig 2, showing the within-group effects, a more gradual increase of immediate recall was
expected in the control group. However, mean immediate recall at four weeks after reaching
adequate blood level of antidepressants was lower (albeit not significantly) than at two weeks
thereafter. Analysis of these data shows that this decreasemight be due to the very low score of
one patient only: after removal of this patient from the sample, the mean value at this assess-
ment returned to a normal range.
In our study, both the RAVLT sub-test for recognition and the VAT failed to detect cogni-
tive impairment. In the vast majority of assessments, scores on the VAT were either 5 or 6; as a
score of 6 indicates a maximum-score on the VAT, this findingmay be indicative of a ceiling
effect of this test.
Confounding factors
Higher age was strongly correlated with a decreased immediate recall function at baseline. This
is consistent with an epidemiological cohort study reporting an association between depressive
symptoms, and poor cognitive functioning and cognitive decline, in particularwith advancing
age [24]. Also, in the absence of depression, age has previously been found to have a significant
effect on performance on the RAVLT [25]. Furthermore, we found that at lower age ECTmay
have a greater impact on immediate recall function.However, we need to consider the possibil-
ity of a floor effect of our test. Most patients in the control group used tricyclic antidepressants,
which may induce cognitive impairment due to their anticholinergic effects [26] and, thereby,
decrease differences in cognitive functioning between the two groups. However, the presumed
cognitive effects of tricyclic antidepressants need further investigation. Percent mood change
during the study was weakly, negatively correlated to improvement of immediate recall func-
tion. However, we also found that adjustment for this covariate resulted in a slight increase in
the interaction effect on delayed recall function. Also, in the control group in our study, greater
depression severity at baseline was positively correlated with a better immediate recall function.
Although this seems counter-intuitive, depression severity may be unrelated to scores on the
immediate and delayed recall subtests of the RAVLT [27]. Therefore, our findingmight be a
misleading result.
Limitations
Methodologically, the main limitations of our study are its naturalistic design, possibly
compromising internal validity, and its small sample size. Furthermore, replacing missing data
by means may result in decreased variability of the data, leading to false-positive results. Some
patients choosing not to participate based their decision on the notion that they considered
themselves incapable/unworthy of participating. Because this might be explained by the sever-
ity of their depression, the most severely depressed patients may be underrepresented in the
present study. In the ECT group, the protocol was violated in 3 (of 11) patients, which may
have affected the outcome data. Although we aimed to match depressed patients receiving ECT
with similar patients treated with antidepressants, these samples may have some inherent
Anterograde Amnesia, Depression and ECT
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differences. Patients were matched for age, gender, and depression severity as measured with
the baseline HRSD score. Nevertheless, patients receiving ECT are likely to differ from patients
treated with antidepressants, i.e. they are either very severely depressed, or there is an acute
indication for ECT (these patients were excluded from participation), or they did not respond
to several adequate trials of antidepressants. Therefore, patients receiving ECT after failure of
pharmacotherapy probably had a longer index episode than patients treated with
antidepressants.
The researchers who collected data were not blinded for the treatment of study-subjects. In
a systematic review comparing randomized clinical trials with both blinded and non-blinded
assessors, the latter were found to have a higher risk of observer bias with subjectivemeasure-
ment scale outcomes [28]. In our study however, we adapted measurement tools with high
test-retest reliability, in an attempt to reduce potential observer bias to a minimum. Also, an
observer bias would hypothetically lead to overestimation of cognitive defects during assess-
ments: since we only found small effects, the true effects of ECT on anterograde memory func-
tion may even be smaller than we described.
Although it would have been unethical to blind our subjects for their treatment, one may
argue, that also study subjects may influence their scores on cognitive functioning tasks based
on their expectancies. Studies on this particularmatter are scarce, however, interestingly, a
recent study found no effects of study subjects' expectation on objective cognitivemeasures
[29]. Also, inherent to clinical research, a Hawthorne effect, in which study subjects tend to
change their behavior when they enter a study, cannot be excluded. This effectmay influence
external validity of clinical studies and has been studied to a very small extent. However, identi-
fying and quantifying this potential effect has proven to be very difficult [30].
Our studied patients received bilateral ECT, which has been associated with increased effi-
cacy in the treatment of MDm compared to right unilateral (RUL) ECT [1]. Bilateral ECT has
also been found to induce greater cognitive side effect than RUL ECT. However, in recent stud-
ies, higher dosages in RUL ECT have been proposed, which may decrease differences in cogni-
tive side-effects between bilateral and high-dose RUL ECT. A recently published study found
no difference in efficacy between bilateral and high-dose RUL ECT, whereas the latter induced
less cognitive side-effects [31].
Future directions
Future research on anterograde amnesia would benefit from including more study subjects and
providing a longer follow-up, preferably up to 6 months after treatment discontinuation. The
risk of relapse in this follow-up period however could pose an extra difficulty for the research-
ers in interpreting the results. Mood change as a covariate may need further exploration.
Another focus for future research, although not discussed in our paper more extensively, may
lie in the use of neuroprotective agents: galantamine may prevent anterograde amnesia in
depressed inpatients who undergo ECT [32].
Conclusion
In the present study, ECT had a significant effect on delayed memory function in patients with
major depression with melancholic features. Effect sizes were large, suggesting that this effect
may relatively easily be detected in clinical practice. Findings related to immediate recall func-
tion were less consistent. Four weeks after treatment discontinuation, these functions had
recovered. Recognition and visual association were not affected, and age was identified as an
important covariate. Overall, the clinical implications of anterograde amnesia caused by ECT
may be small. If our findings can be reproduced in a more comprehensive study, then the
Anterograde Amnesia, Depression and ECT
PLOS ONE | DOI:10.1371/journal.pone.0165392 October 21, 2016 11 / 14
possible induction of anterograde amnesia will not be a justifiable reason for clinicians to disre-
gard ECT as a treatment option in these patients.
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